Pedal the Cause, a community-wide fundraising bike challenge, recently donated $4,743,422 to Siteman Cancer Center and Siteman Kids at St. Louis Children’s Hospital to help fund ongoing cancer research. One hundred percent of the proceeds will go toward research opportunities at both institutions. The record-breaking donation brings the total funds donated by Pedal the Cause over the last 10 years to $29,077,611. This money has funded 130 cancer research projects – including 98 adult and 32 pediatric projects. Funds donated by Pedal the Cause in 2019 will be distributed to the most promising research projects in 2020.
The $4.74 million donation was raised by 3,725 riders and spinners, 522 kids and over 1,107 volunteers who participated in the tenth annual Pedal the Cause – a cycling challenge and weekend community celebration with the goal of curing all cancers for everyone. Pedal the Cause 2019 took place on Sept. 28 and 29 at the Chesterfield Amphitheater. Participants continued to fundraise until Oct. 31.
“On behalf of the entire Pedal the Cause community, we are honored to support best-in-class research at our world-class St. Louis beneficiaries, the Siteman Cancer Center and Siteman Kids at St. Louis Children’s Hospital,” Pedal the Cause Executive Director Jay Indovino said. “These funds will stay in St. Louis and move the frontier forward in cancer research; supporting new treatments, cures and diagnostics for cancer patients here and around the world. We’ll keep riding our bikes and raising critical funds until we have a ‘world without cancer.’”
With over 40,000 donors in 2019, Pedal the Cause remains the region’s largest peer-to-peer fundraising event.
“The support of the St. Louis community through Pedal the Cause has been vital to us as we advance discoveries and cures for the tens of thousands of patients at Siteman Cancer Center and Siteman Kids,” said BJC President and Chief Executive Officer Rich Liekweg. “This remarkable gift from Pedal the Cause will go to work immediately as we push towards a future without cancer and continue to lead the field as a top-tier research institution.”